Aspira Pathlab Diagnostics Ltd vs Gujarat Kidney Super Speciality Ltd Stock Comparison
Aspira Pathlab Diagnostics Ltd vs Gujarat Kidney Super Speciality Ltd Stock Comparison
Last Updated on: Oct 24, 2026
Key Highlights
The Latest Trading Price of Aspira Pathlab & Diagnostics Ltd is ₹ 143.34 as of 29 Sep 10:20
. The P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 0 on March 2026 . This represents a CAGR of -100.00% over 3 yearsThe P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 years The Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 4 yearsThe Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 years The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00%
The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 9 quarters. This represents a CAGR of 29.77%
The Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .
About Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
ASDL is a leading pathology specialist, with Pan-India presence.
It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services.
Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai.
ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.
About Gujarat Kidney & Super Speciality Ltd
Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad.
The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.
FAQs for the comparison of Aspira Pathlab & Diagnostics Ltd and Gujarat Kidney & Super Speciality Ltd
Which company has a larger market capitalization, Aspira Pathlab & Diagnostics Ltd or Gujarat Kidney & Super Speciality Ltd?
Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr while Market cap of Gujarat Kidney & Super Speciality Ltd is 1,395 Cr
What are the key factors driving the stock performance of Aspira Pathlab & Diagnostics Ltd and Gujarat Kidney & Super Speciality Ltd?
The stock performance of Aspira Pathlab & Diagnostics Ltd and Gujarat Kidney & Super Speciality Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Aspira Pathlab & Diagnostics Ltd and Gujarat Kidney & Super Speciality Ltd?
As of October 24, 2026, the Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05. On the other hand, Gujarat Kidney & Super Speciality Ltd stock price is INR ₹176.95.
How do dividend payouts of Aspira Pathlab & Diagnostics Ltd and Gujarat Kidney & Super Speciality Ltd compare?
To compare the dividend payouts of Aspira Pathlab & Diagnostics Ltd and Gujarat Kidney & Super Speciality Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.